This study was a non-interventional, retrospective study collecting data from hospital medical records. Approximately 200 adult patients with moderate to severe plaque psoriasis who were treated with secukinumab from hospitals in Thailand that participated in this study were expected for data collection.
The study was performed in 7 study sites in Thailand and planned to involve approximately 200 medical records. At each study site, patients who were treated with secukinumab or had ever been treated with secukinumab for moderate to severe plaque psoriasis were included for screening by chronological order starting from the most recent date (April 2021) to September 2017. This was to include the most recent clinical practice in the study. The data of patients diagnosed with moderate-to-severe chronic plaque-type psoriasis who received secukinumab in real clinical practice at least 1 dose were collected. The medical records were reviewed to collect the data from the date of the first diagnosis of psoriasis till the most recent dose of secukinumab. The data of secukinumab use and clinical outcome (PASI score) were collected at 4 and 16 weeks after first dose initiation and at the most recent dose of secukinumab. The total number of secukinumab injections at the 3-time points were collected. An index date was defined for each patient. The first secukinumab injection observed in the medical records was considered the index date for the exploratory endpoint.
Study Type
OBSERVATIONAL
Enrollment
163
all patients with psoriasis who received secukinumab
Novartis Investigative Site
Bangkok, Thailand
Age
Age information was reported.
Time frame: Baseline
Gender
Gender information was reported.
Time frame: Baseline
Number of patients with Reimbursement scheme
Reimbursement scheme information was reported.
Time frame: Baseline
Weight
Weight information was reported.
Time frame: During 3 months pre-baseline
Height
Height information was reported.
Time frame: During 3 months pre-baseline
BMI
BMI information was reported.
Time frame: During 3 months pre-baseline
Co-morbidities
* Crohn's Disease * Diabetes Mellitus * Dyslipidemia * Hypertension * Inflammatory Bowel Disease * Latent Tuberculosis * Psoriatic Arthritis (PsA)
Time frame: During 12 months pre-baseline
Psoriasis Area and Sensitivity Index (PASI) score
Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease).
Time frame: During 4 weeks pre-baseline
Percentage of Body Surface Area (BSA) involvement
Percentage of Body Surface Area (BSA) involvement was reported.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: During 4 weeks pre-baseline
Disease Life Quality Index (DLQI) score
The Dermatology Life Quality Index (DLQI) is a simple, self-administered and user-friendly validated questionnaire. The DLQI is designed to measure the health-related quality of life of adult patients suffering from a skin disease. The DLQI is a validated, 10-question, self-reported questionnaire to evaluate the patient's perception of the impact of psoriasis on quality of life. The DLQI was rated on a 4-point scale (0 = not at all to 3 = very much). The highest possible total score for the DLQI is 30 and higher scores indicate more severe impact on quality of life.
Time frame: During 4 weeks pre-baseline
Date of first symptom of psoriasis (PSO) / year
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
Date of psoriasis diagnosis / year
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
Duration of psoriasis diagnosis
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
Date of first systemic treatment/ year
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
Date of first biologic agent/year
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
Duration of topical therapy
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
History of topical therapy
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
Duration of systemic therapy
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
History of systemic therapy
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
Duration of biologic therapy
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
History of biologic therapy
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
Date of PsA diagnosis/year
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
Duration of PsA diagnosis
To describe the PSO treatment history
Time frame: Approximately 2 years pre-baseline (PSO diagnosed date to index date, where index date is defined as date of initiation of treatment)
Number of patients with baseline PSO treatment
Topical Therapies * Topical corticosteroid * Coal tar * Salicylic acid * Vitamin D analogues * Anthralin * Calcineurin inhibitors * Others Oral systemic therapies * Methotrexate * Acitretin * Retinoid * Cyclosporine * Azathioprine * Hydroxyurea * Leflunomide * Sulfasalazine * Others Biologic therapy * Infliximab * Etanercept * Ustekinumab * Brodalumab * Guselkumab * Ixekizumab * Others
Time frame: During 12 months pre-baseline
Duration since the discontinuation of the latest biological agents
Secukinumab therapy
Time frame: Baseline
Medication use concomitant to index secukinumab prescription
Secukinumab therapy
Time frame: Baseline
Treatment pattern with secukinumab
Secukinumab therapy
Time frame: Baseline
Treatment duration since the first dosing till the most recent dosing
Secukinumab therapy
Time frame: Baseline